Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100000 participants
OBSERVATIONAL
2008-08-01
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Question 1: In addition to the established EBV-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether EBV is associated with other cancer types? Question 2: What's the cancer burden attributed to EBV in Southern China?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
NCT04085900
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
NCT00393224
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
NCT06321939
Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection
NCT06895551
Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
NCT03869814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zhongshan cohort, Guangdong, China
30-59 years old healthy participants in Zhongshan city.
Diagnostic test: EBV antibody tests
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Wuzhou cohort, Guangxi, China
30-69 years old healthy participants in Wuzhou city.
Diagnostic test: EBV antibody tests
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic test: EBV antibody tests
Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has no medical record of prevalent cancer;
* Subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\'s follow-up procedures.
Exclusion Criteria
* Subject has prevalent cancer.
30 Years
69 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuzhou Red Cross Hospital
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jia wei-hua
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan People's Hospital
Zhongshan, Guangdong, China
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBV-PRO-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.